Christopher Ogden, Chief Financial Officer at CytomX Therapeutics, Inc. (CTMX), sold 12,255 shares at $2.69 ($33K) on 2025-06-16, disclosed to the SEC on 2025-06-17.
Open-market sale of $33k CTMX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.95 | 1,641 | $5K | 14.5% |
| 2 | $2.69 | 10,614 | $29K | 85.5% |
| Total | $2.72 avg | 12,255 | $33K | 100% |
| Filing → |
| CTMX | SELL | 2025-03-20 | $5K | — | Filing → |
| CTMX | SELL | 2024-08-22 | $2K | — | Filing → |
| CTMX | SELL | 2024-03-21 | $6K | — | Filing → |